Understanding the Brain


From Cognopedia
Jump to: navigation, search

Caprylidene (trade name Axona) is a medical food that was approved in March 2009 by the U.S. Food and Drug Administration for the "clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease".[1] Glucose metabolism by the brain is impaired in Alzheimer's disease, and it is proposed that ketone bodies may provide an alternative energy source. Caprylidene is a powdered form of caprylic triglyceride, a medium chain triglyceride (MCT) in which three molecules of caprylic acid are esterified with glycerol.[2]

See also


  1. FDA-Approved Drugs 2009: Axona (caprylidene) CenterWatch. Cited 30 November 2009.
  2. Axona Drugs.com. Cited 30 November 2009.

Further reading

  1. REDIRECTTemplate:PubMed.

External links